Dept of Respiratory Medicine, Hôpital Tenon AP-HP, Université Paris 6 Pierre et Marie Curie, Paris, France.
These authors contributed equally.
Eur Respir J. 2018 Feb 14;51(2). doi: 10.1183/13993003.02072-2017. Print 2018 Feb.
In May 2017, the second European Respiratory Society research seminar of the Thoracic Oncology Assembly entitled "Immunotherapy, a new standard of care in thoracic malignancies?" was held in Paris, France. This seminar provided an opportunity to review the basis of antitumour immunity and to explain how immune checkpoint inhibitors (ICIs) work. The main therapeutic trials that have resulted in marketing authorisations for use of ICIs in lung cancer were reported. A particular focus was on the toxicity of these new molecules in relation to their immune-related adverse events. The need for biological selection, currently based on immunohistochemistry testing to identify the tumour expression of programmed death ligand (PD-L)1, was stressed, as well as the need to harmonise PD-L1 testing and techniques. Finally, sessions were dedicated to the combination of ICIs and radiotherapy and the place of ICIs in nonsmall cell lung cancer with oncogenic addictions. Finally, an important presentation was dedicated to the future of antitumour vaccination and of all ongoing trials in thoracic oncology.
2017 年 5 月，欧洲呼吸学会胸肿瘤学大会的第二次研究研讨会以“免疫疗法，胸部恶性肿瘤的新标准？”为主题在法国巴黎举行。本次研讨会提供了一个机会来回顾抗肿瘤免疫的基础，并解释免疫检查点抑制剂（ICI）的作用机制。报告了主要的治疗试验，这些试验导致了免疫检查点抑制剂在肺癌中的应用获得了上市许可。特别关注的是这些新分子与免疫相关不良事件相关的毒性。强调了基于生物标志物选择的必要性，目前基于免疫组织化学检测来确定肿瘤程序性死亡配体（PD-L）1 的表达，以及需要协调 PD-L1 检测和技术。最后，会议专门讨论了 ICI 与放疗的联合应用以及 ICI 在有致癌性驱动基因改变的非小细胞肺癌中的地位。最后，一个重要的演讲专门介绍了抗肿瘤疫苗的未来和胸肿瘤学领域所有正在进行的试验。
